Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Nov;16(11):1431-2.
doi: 10.1093/neuonc/nou285. Epub 2014 Oct 14.

Timing (and biology) are everything

Howard A Fine  1
Affiliations
Editorial

Timing (and biology) are everything

Howard A Fine. Neuro Oncol. 2014 Nov.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

References

    1. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233–242. - PMC - PubMed
    1. Rahman R, Hempfling K, Norden AD, et al. Retrospective study of using carmustine or lomustine with bevacizumabin recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014;16:1523–1529. - PMC - PubMed
    1. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729. - PubMed
    1. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;10:740–745. - PMC - PubMed
    1. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8:189–193. - PMC - PubMed

MeSH terms